Análisis de la acción Aligos Therapeutics, Inc. (ALGS)ALGSAligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Aligos Therapeutics Inc is a good buy right now due to its recent positive developments and strong analyst support. The current price is $6.91, while analysts have set price targets as high as $60, suggesting significant upside potential. Additionally, the company has shown a remarkable 63.36% increase over the last 20 days, indicating positive momentum. However, investors should be cautious of the risk of a net loss of $1.5 million reported in Q2 2026, which, while improved from previous losses, still reflects ongoing challenges.